EA201391773A1 - Клетки-предшественники мезодермальной линии - Google Patents

Клетки-предшественники мезодермальной линии

Info

Publication number
EA201391773A1
EA201391773A1 EA201391773A EA201391773A EA201391773A1 EA 201391773 A1 EA201391773 A1 EA 201391773A1 EA 201391773 A EA201391773 A EA 201391773A EA 201391773 A EA201391773 A EA 201391773A EA 201391773 A1 EA201391773 A1 EA 201391773A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
precursors
line
mesodermal
mesodermal line
Prior art date
Application number
EA201391773A
Other languages
English (en)
Other versions
EA029577B1 (ru
Inventor
Томас Эверилл Хауз
Мартин Джон Эванс
Аджан Реджинальд
Ина Лаура Пипер
Брайан Ли Перкинс
Original Assignee
Селл Терапи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1111503.7A external-priority patent/GB201111503D0/en
Priority claimed from GBGB1111509.4A external-priority patent/GB201111509D0/en
Priority claimed from GBGB1111500.3A external-priority patent/GB201111500D0/en
Priority claimed from GBGB1111505.2A external-priority patent/GB201111505D0/en
Application filed by Селл Терапи Лимитед filed Critical Селл Терапи Лимитед
Publication of EA201391773A1 publication Critical patent/EA201391773A1/ru
Publication of EA029577B1 publication Critical patent/EA029577B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Настоящее изобретение относится к клеткам-предшественникам мезодермальной линии и их применению в терапии.
EA201391773A 2011-07-06 2012-07-06 Клетки-предшественники мезодермальной линии EA029577B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1111503.7A GB201111503D0 (en) 2011-07-06 2011-07-06 Heart failure (HF) MSC subtype
GBGB1111509.4A GB201111509D0 (en) 2011-07-06 2011-07-06 Orthopedic MSC subtype
GBGB1111500.3A GB201111500D0 (en) 2011-07-06 2011-07-06 Wet age-related macular degeneration MSC subtype
GBGB1111505.2A GB201111505D0 (en) 2011-07-06 2011-07-06 MI MSC subtype
PCT/GB2012/051600 WO2013005053A2 (en) 2011-07-06 2012-07-06 Progenitor cells of mesodermal lineage

Publications (2)

Publication Number Publication Date
EA201391773A1 true EA201391773A1 (ru) 2014-11-28
EA029577B1 EA029577B1 (ru) 2018-04-30

Family

ID=46513785

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391773A EA029577B1 (ru) 2011-07-06 2012-07-06 Клетки-предшественники мезодермальной линии

Country Status (19)

Country Link
US (3) US10472609B2 (ru)
EP (1) EP2729562B1 (ru)
JP (2) JP6607675B2 (ru)
CN (2) CN107746830A (ru)
AU (2) AU2012279995C1 (ru)
CA (1) CA2840307C (ru)
CY (1) CY1120646T1 (ru)
DK (1) DK2729562T3 (ru)
EA (1) EA029577B1 (ru)
ES (1) ES2675693T3 (ru)
HR (1) HRP20181152T1 (ru)
HU (1) HUE039236T2 (ru)
IL (2) IL230071B (ru)
LT (1) LT2729562T (ru)
MY (1) MY185016A (ru)
PL (1) PL2729562T3 (ru)
PT (1) PT2729562T (ru)
SG (1) SG10201605518XA (ru)
WO (1) WO2013005053A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6184971B2 (ja) 2011-11-23 2017-08-23 セル セラピー リミテッドＣｅｌｌ Ｔｈｅｒａｐｙ Ｌｉｍｉｔｅｄ 血小板溶解物ゲル
CN106255884B (zh) * 2013-10-04 2019-01-11 赛尔爱迪尔私人有限公司 用于细胞治疗的生物标志物
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
GB201410504D0 (en) * 2014-06-12 2014-07-30 Cell Therapy Ltd Immuno-modulaltory progenitor (IMP) cell
WO2016032967A1 (en) * 2014-08-29 2016-03-03 Becton, Dickinson And Company Methods and compositions for obtaining a tuberculosis assessment in a subject
JP2018512061A (ja) * 2015-02-20 2018-05-10 ナショナル ヤン−ミン ユニバーシティ 骨関節炎処置のための間葉幹細胞の使用
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
GB201513996D0 (en) 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
WO2017043666A1 (ja) * 2015-09-11 2017-03-16 アステラス製薬株式会社 腎前駆細胞を製造する方法
GB201518263D0 (en) 2015-10-15 2015-12-02 Oxford Bioelectronics Ltd Method
CN105483206B (zh) * 2016-01-06 2019-09-13 北京汉氏联合生物技术股份有限公司 一种用vcam-1检测msc促内皮细胞增殖能力的方法
KR102396303B1 (ko) * 2016-08-29 2022-05-09 해컨색 유니버시티 메디컬 센터 혈소판-유사 세포를 함유하는 혈액의 혈소판 풍부 분획을 이용하여 성체 세포를 재프로그래밍하기 위한 조성물 및 방법
CN109843317A (zh) * 2016-08-29 2019-06-04 哈肯萨克大学医学中心 通过人中含有血小板样细胞的血液的富含血小板级分的干性用于使成体细胞重编程的组合物和方法
JP7009977B2 (ja) 2017-12-25 2022-01-26 国立大学法人東海国立大学機構 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
ES2970156T3 (es) * 2018-11-14 2024-05-27 Onderzoeks En Ontwikkelingsfonds Rode Kruis Vlaanderen Métodos para preparar un liberado de plaquetas
CN109329270A (zh) * 2018-11-19 2019-02-15 成都清科生物科技有限公司 一种静脉回输用间充质干细胞保存液及其制备方法
WO2020148520A1 (en) 2019-01-15 2020-07-23 Cell Therapy Limited Mesodermal killer (mk) cell
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
WO2020157660A1 (en) * 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
JP2022533949A (ja) * 2019-05-15 2022-07-27 ステムサイト インコーポレーテッド 高濃度細胞のパッケージングおよび輸送
CN110237094B (zh) * 2019-07-30 2023-10-03 天晴干细胞股份有限公司 一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
RU2138162C1 (ru) 1997-04-17 1999-09-27 Суханов Владимир Александрович Способ криоконсервации богатой тромбоцитами плазмы
PT1028737E (pt) 1997-07-03 2007-07-11 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas de sangue periférico
WO1999011287A1 (en) 1997-09-04 1999-03-11 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
AU4221399A (en) 1998-05-29 1999-12-13 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
JP2003055237A (ja) * 2001-08-15 2003-02-26 Japan Science & Technology Corp 骨再生促進剤
ATE365793T1 (de) 2002-02-19 2007-07-15 Medipost Co Ltd Verfahren zur isolierung und kulturexpansion mesenchymaler stamm-/vorläuferzellen aus nabelschnurblut sowie verfahren zur differenzierung von aus nabelschnurblut stammenden mesenchymalen stamm-/vorläuferzellen in unterschiedliche mesenchymgewebe
KR100534215B1 (ko) 2003-11-11 2005-12-08 (주)히스토스템 냉동 보관된 제대혈로부터 중간엽 줄기세포의 분리 및 배양 방법
DE102005011568A1 (de) 2004-04-13 2005-11-17 Man Roland Druckmaschinen Ag Produktionsverfahren für eine Prägeeinrichtung in einer Bogendruckmaschine
ATE494360T1 (de) 2004-07-20 2011-01-15 Univ Case Western Reserve Neue zellpopulationen und deren anwendungen
EP2361970A1 (en) 2004-09-24 2011-08-31 Angioblast Systems Incorporated Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
CN101506355B (zh) 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代（memp）及其应用
EP1869165B1 (en) 2005-04-12 2015-10-21 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
KR100679642B1 (ko) * 2005-11-16 2007-02-06 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
AU2007208504B2 (en) 2006-01-13 2011-04-21 Mesoblast International Sarl Mesenchymal stem cells expressing TNF-alpha receptor
EP1845154A1 (en) 2006-04-12 2007-10-17 RNL Bio Co., Ltd. Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same
EP2046349B1 (en) 2006-07-12 2015-09-09 Mesoblast, Inc. Treatment of excessive neovascularization
US20090253151A1 (en) 2006-09-01 2009-10-08 Stempeutics Research Private Limited Self-Renewing Master Adult Pluripotent Stem Cells
WO2008097828A2 (en) 2007-02-02 2008-08-14 St. Jude Children's Research Hospital Method for isolating mesenchymal stromal cells
WO2008129563A2 (en) 2007-04-23 2008-10-30 Stempeutics Research Private Limited, Human mesenchymal stem cells and preparation thereof
US20090053182A1 (en) 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
EP2014294A1 (en) 2007-07-13 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of CD200 as a mesenchymal stem cells marker
KR100970753B1 (ko) 2007-10-01 2010-07-16 재단법인서울대학교산학협력재단 광화능을 갖는 인간 치아 줄기세포 및 그의 배양방법
JP5319682B2 (ja) 2007-11-09 2013-10-16 アールエヌエル バイオ カンパニー リミテッド ヒト羊膜上皮由来の成体幹細胞の分離及び培養方法
WO2009069991A2 (en) * 2007-11-30 2009-06-04 Rnl Bio Co., Ltd. Cellular therapeutic agent for incontinence of urine comprising stem cells originated from decidua or adipose
US20110182866A1 (en) 2008-05-15 2011-07-28 University Of Miami Isolation of stem cell precursors and expansion in non-adherent conditions
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
JP2011529706A (ja) 2008-08-04 2011-12-15 アローキュア インコーポレイテッド 間充織間質細胞集団、ならびにそれを単離および使用する方法
EP3121597A1 (en) 2008-08-18 2017-01-25 Mesoblast, Inc. Monoclonal antibody stro-4
US20110177041A1 (en) * 2008-08-22 2011-07-21 Misako Nakashima Material for treatment of cerebral infarction and brain tissue regeneration method
EP3584310B1 (en) 2008-09-16 2024-04-17 Mayo Foundation for Medical Education and Research Compositions containing platelet contents
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
EP2350266B1 (en) 2008-11-20 2015-07-29 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
DK2425844T3 (da) 2009-04-28 2014-06-16 Anterogen Co Ltd Autolog og allogen stromastamcellesammensætning, der stammer fra fedtvæv, til behandling af fistler
AU2010306833A1 (en) 2009-10-13 2012-05-10 Allocure Inc. Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
ES2358146B1 (es) 2009-10-22 2012-03-23 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis.
US20120269779A1 (en) 2009-10-30 2012-10-25 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
CN102048756B (zh) 2009-11-04 2014-02-19 中国医学科学院基础医学研究所 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途
WO2011068792A2 (en) 2009-12-01 2011-06-09 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
CA2803641A1 (en) 2010-07-02 2012-01-05 Mesoblast, Inc. Treatment of t-cell mediated immune disorders
US20140023621A1 (en) 2010-08-27 2014-01-23 University Of Miami Bone marrow derived cd271 precursor cells for cardiac repair
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
ES2384790B1 (es) 2010-12-10 2013-05-20 Instituto De Salud Carlos Iii Células madre mesenquimales aisladas a partir de sangre periférica.
US20120288480A1 (en) 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
CN102078644A (zh) * 2011-03-08 2011-06-01 吉林大学 一种简便高效的自体富血小板血浆提取装置及提取方法
EP2709634B1 (en) 2011-05-19 2020-09-09 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
CN103826646A (zh) 2011-06-03 2014-05-28 麦瑟布莱斯特公司 治疗中风的影响的方法
CA2837895C (en) 2011-06-03 2021-07-27 Mesoblast, Inc. Methods of treating or preventing neurological diseases
EP3653218A1 (en) 2011-07-04 2020-05-20 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
TR201809635T4 (tr) 2011-09-09 2018-07-23 Mesoblast Inc Osteoblastik fonksiyonun arttırılmasına yönelik yöntemler.
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US20150064141A1 (en) 2012-04-05 2015-03-05 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome

Also Published As

Publication number Publication date
DK2729562T3 (en) 2018-07-23
LT2729562T (lt) 2018-07-25
HUE039236T2 (hu) 2018-12-28
WO2013005053A2 (en) 2013-01-10
US10472609B2 (en) 2019-11-12
IL230071B (en) 2019-02-28
SG10201605518XA (en) 2016-08-30
AU2012279995B2 (en) 2017-03-30
PT2729562T (pt) 2018-07-18
JP2014520523A (ja) 2014-08-25
US20210032600A1 (en) 2021-02-04
PL2729562T3 (pl) 2018-10-31
WO2013005053A3 (en) 2013-06-13
AU2012279995A1 (en) 2014-01-23
CN104508124A (zh) 2015-04-08
CY1120646T1 (el) 2019-12-11
CA2840307C (en) 2021-10-19
US20150071886A1 (en) 2015-03-12
EP2729562A2 (en) 2014-05-14
MY185016A (en) 2021-04-30
IL264455A (en) 2019-02-28
JP2017225451A (ja) 2017-12-28
AU2017204559A1 (en) 2017-07-20
US20200048613A1 (en) 2020-02-13
EP2729562B1 (en) 2018-04-18
NZ620283A (en) 2016-06-24
EA029577B1 (ru) 2018-04-30
US10829739B2 (en) 2020-11-10
JP6607675B2 (ja) 2019-11-20
HRP20181152T1 (hr) 2018-09-21
US11873513B2 (en) 2024-01-16
AU2012279995C1 (en) 2019-10-24
CN104508124B (zh) 2017-11-17
CA2840307A1 (en) 2013-01-10
CN107746830A (zh) 2018-03-02
ES2675693T3 (es) 2018-07-11

Similar Documents

Publication Publication Date Title
EA201391773A1 (ru) Клетки-предшественники мезодермальной линии
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
UA117008C2 (uk) IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201590807A1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201290590A1 (ru) Модифицированные туберкулезные антигены
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
EA201391248A1 (ru) Биспецифические связывающие агенты
IN2014DN06104A (ru)
TWD159981S (zh) 化粧品容器
TWD158887S (zh) 粉餅盒
BR112015012907A2 (pt) composição de cuidado pessoal
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
IN2014CN03625A (ru)
MX2016000313A (es) Estabilizadores de luz novedosos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG TJ TM